Optimising Pacing for Contractility 2
Recruiting
Phase 2
Phase 3
Interventional Study
Heart Failure, Systolic
Pacemaker
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 400 (estimated)
- Sponsor
- University of Leeds · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF). They have also demonstrated in an acute cross-over and a small parallel group feasibility study that keeping the heart rate in this range (versus standard rate-response programming) in patients with CHF is associated w…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Clinical, echocardiographic and neurohormonal evidence of heart failure
* Cardiac pacemaker,
* Able to perform a peak exercise test,
* Willing and able to give informed consent.
Exclusion Criteria:
* Angina pectoris symptoms limiting exercise tolerance,
* Unstable heart fail…
Contacts